Syngeneic Mouse Models
Custom-made solutions and validated tumor models to accelerate your oncology research.
Syngeneic tumor models are an essential part of preclinical immunotherapy research. But with limited data and without an exact-match tumor model your research aspirations can become stunted.
Melior creates customized models and experiments that meet your needs. When you partner with Melior you can confidently and efficiently perform in vivo efficacy evaluations of potential cancer therapies. These include targeted therapy, cytotoxic drugs, antibody therapies, checkpoint inhibitors and gene therapies.
Secure early access to the right model and get data that pushes your oncology R&D forward.
Confidently test your immunotherapeutic agents and combination therapies with syngeneic tumor models
Because syngeneic mouse tumors are immunologically compatible with their host, tumor transplantation does not provoke an immune response. Instead, tumors grow within an intact immune system. This system provides valuable models for studying therapies that act on the host immune system. With Melior’s syngeneic mouse tumor models, you can develop cancer therapies that work together with the immune system to reduce and reverse tumor growth, as with checkpoint inhibitors.
Advantages of using syngeneic tumor models
- Explore cancer immunotherapies: Get relevant data and better understand the mechanisms of action of new therapeutics targeting immune cell interactions.
- Leverage models with fully competent immunity: Enable studies on the interaction between tumor cells, immune cells, microcroenvironment, and microbiome
- Benefit from simple, cost-saving solutions: Generate reliable results with animals inherently less expensive than xenograft models
Advance your discoveries with our validated syngeneic mouse models
Start your research on the right track by leveraging our expertise and outsourcing your in vivo experiments. Test your immunotherapeutic agents and combination therapies in any of our validated syngeneic tumor models.
- Breast Cancer – EMT6 Cells
- Colon Cancer – CT26 Cells
- Leukemia – L120 Cells
- Liver Cancer – Hepa1-6 Cells
- Lung Cancer – LLC Cells
- Melanoma – B16F10 Cells
- Pancreatic – KPCY Cells and TGP47 Cells
- Sarcoma – WEHI164 Cells
Don’t see what you’re looking for? Contact us for information on other validated models or to discuss a custom solution.
Enhance your study findings with custom services and tools
Seamlessly integrate a range of services and additional analyses to get the most out of your study. Some of our services include:
- IVIS imaging
- Whole blood, spleen, and lymph node analysis
- Histology and IHC
- PK studies
- General observations
- Metabolic analyses
- Pain analysis
Don’t see what you’re looking for on this list? Tell us what you’re looking for.
Get the data you need with customized experiments and expert advice
Find specific models, collect custom data, and enjoy a fast turnaround time.
Flexibility and Customization
Unique research questions deserve unique study designs. That’s why we custom-tailor our models and experiments to fit your needs. By developing models for specific research objectives, we help you ask the tough questions and get the data you need to move forward with confidence.
Short Lead Times
Reach your discoveries sooner with industry-leading 4-7 week lead times. While larger CROs have wait times up to a year, our unique positioning gets you started quickly and delivers results faster.
Quality and Expertise
Our lean company has decades worth of experience in a wide range of research areas. This expertise starts at the top. Dr. Li, our Director of Oncology, managed the cancer in vivo model core facility at Sloan Kettering Cancer Center for over 8 years.
You deserve to know exactly what’s going on with your research. Melior’s open-door process ensures you’re never left in the dark. Our individualized approach cultivates a collaborative relationship among both clients and team members.
Data Highlight: Checkpoint Inhibitors and Taxanes
Subcutaneous Models vs Orthotopic Models
Standard subcutaneous models are an efficient choice for measuring tumor response to a new drug. This method involves implanting tumor cells into the flank of a mouse and monitoring growth. Tumors grow efficiently in this model. It allows for analyses such as drug efficacy and endpoint analyses, including survival, flow cytometry, expression analysis, histology, and more.
Orthotopic models, on the other hand, involve seeding tumor cell lines into the corresponding mouse tissue. This strategy assesses tumor development in a relevant tissue environment that mimics the disease process in humans. With orthotopic models, we can monitor and more accurately quantify primary tumor growth, metastatic activity, and response to therapy.
Are syngeneic tumor models right for you?
A syngeneic tumor model only applies to rodent-derived tumors because it relies on the animals’ immune system to remain intact. If you need human-derived tumors, or your cancer type is not available in a syngeneic mouse model, you may want to consider our xenograft models.
Xenograft models offer a wider range of cancer types and produce data that may be more readily translatable to human studies.